Please login to the form below

Not currently logged in
Email:
Password:

lifitegrast

This page shows the latest lifitegrast news and features for those working in and with pharma, biotech and healthcare.

Shire files dry eye drug lifitegrast in Europe

Shire files dry eye drug lifitegrast in Europe

Shire files dry eye drug lifitegrast in Europe. Analysts predict Xiidra could become a $1bn product. ... Once fully rolled out, analysts have suggested lifitegrast could become a $1bn product for Shire within the next five years.

Latest news

  • Shire licences Parion dry eye drug in $535m deal Shire licences Parion dry eye drug in $535m deal

    All told the deal could be worth up to $535m for North Carolina biotech Parion, while Shire adds to the pipeline behind its recently-approved dry eye disease therapy Xiidra (lifitegrast).

  • Shire launches dry eye drug Xiidra in US Shire launches dry eye drug Xiidra in US

    The Anglo-Irish company is making much of that fact that Xiidra (lifitegrast) - the first in a new class of lymphocyte function-associated antigen 1 (LFA-1) antagonist - is the only

  • FDA finally approves Shire’s potential blockbuster Xiidra FDA finally approves Shire’s potential blockbuster Xiidra

    The only prescription eye drop indicated for the treatment of both signs and symptoms of this condition, Xiidra (lifitegrast ophthalmic solution) is taken twice a day. ... says. Lifitegrast, which was licensed from SARcode Bioscience in 2013, is a

  • FDA deals a big blow to Shire's late-stage pipeline FDA deals a big blow to Shire's late-stage pipeline

    Shire suffered a major setback last week when the FDA declined to approve its lifitegrast treatment for dry eye disease, which has been tipped as a $1bn product. ... Lifitegrast is a small molecule integrin beta(2) antagonist that the company licensed

  • Shire buys into eyecare specialist Shire buys into eyecare specialist

    Shire buys into eyecare specialist. Will complement its investigational dry eye drug lifitegrast. ... It is highly synergistic with the planned lifitegrast commercial structure. FST-100 and lifitegrast, if approved, would address two of the leading

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    Shire's second acquisition of the month was also in the field of ophthalmology bringing SARcode Bioscience for $160m plus additional milestones with its phase III stage product Lifitegrast for dry ... Lifitegrast is a small-molecule integrin antagonist

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics